MA44836A - Procédés de traitement du syndrome polykystique des reins - Google Patents

Procédés de traitement du syndrome polykystique des reins

Info

Publication number
MA44836A
MA44836A MA044836A MA44836A MA44836A MA 44836 A MA44836 A MA 44836A MA 044836 A MA044836 A MA 044836A MA 44836 A MA44836 A MA 44836A MA 44836 A MA44836 A MA 44836A
Authority
MA
Morocco
Prior art keywords
treatment methods
syndrome treatment
polycystic syndrome
kidney
kidney polycystic
Prior art date
Application number
MA044836A
Other languages
English (en)
Inventor
John R Androsavich
B Nelson Chau
Vishal D Patel
Original Assignee
Univ Texas
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA44836A publication Critical patent/MA44836A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy

Abstract

La présente invention concerne des procédés de traitement d'une maladie rénale polykystique, y compris une maladie rénale polykystique autosomique dominante, utilisant des oligonucléotides modifiés ciblés sur mir-17.
MA044836A 2015-08-26 Procédés de traitement du syndrome polykystique des reins MA44836A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210031P 2015-08-26 2015-08-26

Publications (1)

Publication Number Publication Date
MA44836A true MA44836A (fr) 2018-07-04

Family

ID=56855838

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044836A MA44836A (fr) 2015-08-26 Procédés de traitement du syndrome polykystique des reins

Country Status (15)

Country Link
US (3) US10633657B2 (fr)
EP (2) EP3340993B1 (fr)
JP (1) JP6929269B2 (fr)
KR (1) KR20180080181A (fr)
CN (2) CN108135922A (fr)
AU (1) AU2016312590B2 (fr)
CA (1) CA2995996A1 (fr)
DK (1) DK3340993T3 (fr)
ES (1) ES2954151T3 (fr)
HK (1) HK1256883A1 (fr)
IL (1) IL257596B (fr)
MA (1) MA44836A (fr)
MX (1) MX2018002354A (fr)
RU (1) RU2742300C2 (fr)
WO (1) WO2017035319A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3044896A1 (fr) * 2016-12-05 2018-06-14 Charles R. ALLERSON Oligonucleotides modifies pour traiter la polykystose renale
KR20190093207A (ko) * 2016-12-05 2019-08-08 레굴루스 테라퓨틱스 인크 다낭성 신장 질환의 치료 방법
WO2020038968A1 (fr) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Biomarqueur de microarn-134
WO2024026354A2 (fr) * 2022-07-27 2024-02-01 The General Hospital Corporation Procédés et compositions destinés à être utilisés dans le traitement d'une maladie rénale polykystique récessive autosomique (arpkd)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
CA2558020A1 (fr) 2004-03-17 2005-09-29 Novartis Ag Utilisation de composes organiques
JPWO2007126150A1 (ja) * 2006-04-27 2009-09-17 国立大学法人名古屋大学 癌の新規治療用組成物
US20120283411A9 (en) * 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2927045A1 (fr) 2006-10-03 2008-04-10 Muthiah Manoharan Formulations contenant un lipide
WO2008131191A2 (fr) * 2007-04-20 2008-10-30 Amgen Inc. Acides nucléiques hybridables avec des précurseurs des micro-arn de ceux-ci
WO2009143403A1 (fr) * 2008-05-23 2009-11-26 Targacept, Inc. Thérapie combinée de la gestion de l'hypertension
WO2014082644A1 (fr) * 2012-11-30 2014-06-05 WULFF, Peter, Samuel Arn circulaire destiné à l'inhibition de micro-arn
EP3060217B1 (fr) * 2013-10-24 2022-06-08 Mayo Foundation for Medical Education and Research Traitement des maladies polykystiques avec un inhibiteur hdac6
US20160362688A1 (en) 2014-02-12 2016-12-15 Thomas Jefferson University Compositions and methods of using microrna inhibitors
CA3044896A1 (fr) 2016-12-05 2018-06-14 Charles R. ALLERSON Oligonucleotides modifies pour traiter la polykystose renale
KR20190093207A (ko) 2016-12-05 2019-08-08 레굴루스 테라퓨틱스 인크 다낭성 신장 질환의 치료 방법

Also Published As

Publication number Publication date
IL257596A (en) 2018-04-30
WO2017035319A8 (fr) 2021-03-11
IL257596B (en) 2022-08-01
MX2018002354A (es) 2018-12-10
RU2018108206A (ru) 2019-09-27
RU2742300C2 (ru) 2021-02-04
KR20180080181A (ko) 2018-07-11
AU2016312590B2 (en) 2021-12-02
AU2016312590A1 (en) 2018-03-15
DK3340993T3 (da) 2023-08-21
JP6929269B2 (ja) 2021-09-01
RU2018108206A3 (fr) 2020-01-14
EP4268891A3 (fr) 2024-01-24
US20220025372A1 (en) 2022-01-27
HK1256883A1 (zh) 2019-10-04
WO2017035319A1 (fr) 2017-03-02
US10633657B2 (en) 2020-04-28
EP4268891A2 (fr) 2023-11-01
CN114404440A (zh) 2022-04-29
CN108135922A (zh) 2018-06-08
JP2018528945A (ja) 2018-10-04
US20200231971A1 (en) 2020-07-23
US20190153442A1 (en) 2019-05-23
EP3340993A1 (fr) 2018-07-04
EP3340993B1 (fr) 2023-06-14
CA2995996A1 (fr) 2017-03-02
US11168325B2 (en) 2021-11-09
ES2954151T3 (es) 2023-11-20

Similar Documents

Publication Publication Date Title
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201792529A1 (ru) Ингибиторы тирозинкиназы
EA201692370A1 (ru) КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
EA201890394A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
PH12019501224A1 (en) Compositions for treatment of polycystic kidney disease
EA201790867A1 (ru) Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA201790207A8 (ru) Новые замещенные пиримидиновые соединения
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
EA201301336A1 (ru) Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës
MX2017009038A (es) Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
MA41758A (fr) Procédés de traitement de l'infertilité
EA201790209A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde